Establishment Labs Holdings Inc (NASDAQ:ESTA) – Jefferies Financial Group boosted their FY2023 earnings estimates for shares of Establishment Labs in a report released on Tuesday, August 13th, according to Zacks Investment Research. Jefferies Financial Group analyst R. Denhoy now expects that the company will earn $0.28 per share for the year, up from their prior estimate of $0.26.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.08. The company had revenue of $21.68 million for the quarter, compared to analyst estimates of $20.10 million. Establishment Labs had a negative return on equity of 60.43% and a negative net margin of 38.63%.
Other research analysts have also issued research reports about the company. BTIG Research reaffirmed a “buy” rating and set a $40.00 price target on shares of Establishment Labs in a research report on Thursday, May 16th. Wells Fargo & Co set a $29.00 target price on Establishment Labs and gave the company a “buy” rating in a report on Friday, July 12th. Zacks Investment Research lowered Establishment Labs from a “hold” rating to a “sell” rating in a report on Friday, August 16th. ValuEngine raised Establishment Labs from a “hold” rating to a “buy” rating in a report on Monday, July 29th. Finally, Stephens initiated coverage on Establishment Labs in a report on Thursday, June 6th. They issued an “overweight” rating and a $37.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $35.33.
ESTA opened at $19.88 on Thursday. The firm has a market cap of $410.00 million and a price-to-earnings ratio of -17.75. Establishment Labs has a 52 week low of $19.40 and a 52 week high of $30.70. The business’s 50 day moving average is $22.60 and its two-hundred day moving average is $24.02. The company has a quick ratio of 2.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.45.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN acquired a new position in Establishment Labs in the second quarter valued at $479,000. JPMorgan Chase & Co. lifted its holdings in Establishment Labs by 96.3% in the second quarter. JPMorgan Chase & Co. now owns 13,014 shares of the company’s stock valued at $273,000 after buying an additional 6,386 shares during the period. JW Asset Management LLC lifted its holdings in Establishment Labs by 1,840.3% in the second quarter. JW Asset Management LLC now owns 3,104,485 shares of the company’s stock valued at $68,268,000 after buying an additional 2,944,485 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Establishment Labs by 257.1% in the second quarter. Tower Research Capital LLC TRC now owns 1,350 shares of the company’s stock valued at $30,000 after buying an additional 972 shares during the period. Finally, Vanguard Group Inc. acquired a new position in Establishment Labs in the second quarter valued at $349,000. 25.86% of the stock is currently owned by hedge funds and other institutional investors.
In other Establishment Labs news, Director Nicholas Sheridan Lewin acquired 2,700 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were purchased at an average price of $20.11 per share, with a total value of $54,297.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Jw Asset Management, Llc acquired 2,500 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were acquired at an average cost of $25.58 per share, for a total transaction of $63,950.00. The disclosure for this purchase can be found here. In the last three months, insiders bought 13,700 shares of company stock worth $305,902. Corporate insiders own 2.64% of the company’s stock.
About Establishment Labs
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.